{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:43:29Z","timestamp":1786373009635,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.2215\/cjn.10240819","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T16:55:14Z","timestamp":1574096114000},"page":"415-417","source":"Crossref","is-referenced-by-count":11,"title":["Management of Membranous Nephropathy after MENTOR"],"prefix":"10.2215","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct01955187","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03018535","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Claire","family":"Trivin-Avillach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence H.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,11,18]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2017070734","article-title":"Phospholipase A2 receptor 1 epitope spreading at baseline predicts Reduced likelihood of remission of membranous nephropathy","volume":"29","author":"Seitz-Polski","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","article-title":"Immunological remission in PLA2R-antibody-associated membranous nephropathy: Cyclophosphamide versus rituximab","volume":"93","author":"van de Logt","year":"2018","journal-title":"Kidney Int"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.kint.2018.08.045","article-title":"Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody","volume":"95","author":"Dahan","year":"2019","journal-title":"Kidney Int"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.10240819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:41:10Z","timestamp":1786369270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.10240819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,18]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.10240819","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,18]]}}}